Optimizing Treatment Selection and Side Effect Management in BRAF-Mutant Melanoma

Optimizing Treatment Selection and Side Effect Management in BRAF-Mutant Melanoma

Optimizing Treatment Selection and Side Effect Management in BRAF-Mutant Melanoma
RestartResume

Catch up on combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma.

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.

    In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Assess the latest clinical data for doublet and triplet targeted therapy and immunotherapy combinations to optimize treatment selection for, and clinical management of, patients with BRAF-mutant melanoma
    2. Integrate combination targeted therapy and immunotherapy approaches for the treatment of patients with BRAF-mutant melanoma to optimize outcomes
    3. Incorporate knowledge of safety profiles of combination BRAF/MEK inhibitors and immunotherapy to identify and manage treatment-related side effects in patients with BRAF-mutant melanoma
  • Target Audience

    This educational activity is designed for medical oncologists, pathologists/lab professionals, oncology nurses, nurse practitioners, pharmacists, physician assistants, and other healthcare professionals who are part of the interprofessional team responsible for treatment selection and the therapeutic management of patients with BRAF-mutant melanoma.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Jeffrey S. Weber, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Biond Biologics; CytomX; Evaxion Biotech; Genentech, Inc; GlaxoSmithKline; Incyte Corp; Merck & Co, Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc; Regeneron Pharmaceuticals, Inc; and Sellas Life Sciences Group, Inc. Contracted research paid to NYU: Moderna; Merck & Co, Inc; Bristol-Myers Squibb Co; GlaxoSmithKline; and Incyte Corp. Ownership interest: Neximmune, Biond Biologics, and Evaxion Biotech. Patents and royalties: Biodesix, Inc.

    The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD,  BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive  1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/21/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for for 1.0  contact hour of JA4008106-0000-21-079-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0  contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

    Are you requesting ASCP CMLE Credit? If yes, an ASCP CMLE certificate will be emailed to you.

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation

  • Terms of Use

    Disclosure of Unlabeled Use       
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit: 
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free